Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Parke Davis: Uncertainty affects valuation - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 20, 2000

    Parke Davis: Uncertainty affects valuation

    That international mergers create uncertainty is a given. This holds good for the management, the employees as well as the shareholders. A recent example is that of Parke Davis.

    The company till recently was an affiliate of the $ 9 bn Warner Lambert which held 40% in its Indian arm. The takeover of Warner Lambert by Pfizer and the presence of a two parallel 100% subsidiaries in India has led to a uncertainty about the prospects of Parke Davis and this has affected the valuation of the company.

    International media reports have mentioned that Pfizer has cleared out several layers of Warner Lambert management leaving hardly any senior positions for the Warner Lambert staff as it consolidates its acquisition. What way the merger pans out in India remains to be seen.

    In India, Parke Davis has a presence in gynaec care, cardiac care, pediatric care and neuro care. It’s cough syrup Benadryl is the third largest brand in the Rs 4.8 bn cough and colds market after Corex (Pfizer) and Phensedyl (Rhone Poulenc). Its over–the–counter products include Waterbury’s Compound (a health tonic), Gelusil (an antacid), Neko (a bath soap) and Listerine (an oral hygiene product). These contributed nearly 20% to the company’s turnover of Rs 1,793 m last year.

    Over the past two years Parke Davis also launched products such as Walcillin (an amoxycillin based antibiotic), Atpark (cardiovasdcular) and Calcal (a calcium supplement). Though these products are based on much older molecules, they have done well and account for almost 12% of the company’s sales.

    Last year the company sold its Saki Naka plant (in Mumbai) for Rs 493 m. However, the company has still not received the full payment for the same. (The workers of the plant were paid off via a Voluntary Retirement Scheme.)

    Also, the company does not have a reputation for being minority shareholder friendly. A prominent example was the transfer, in the past, of cough lozenges ‘Halls’ and ‘Chiclets’ to the 100% subsidiary of its parent Warner Lambert India.

    Coming to the financials, the company reported a 15% growth in its net profit in the first half of the current year. The write off of VRS expenditure was completed last year and this has led to a higher tax payment in the current year. At the current price of Rs 267, the stock price implies an earning multiple of 17 times its annualised earnings of FY01. This is relatively lower than the earnings multiples enjoyed by its peers. Keeping in mind the uncertainty regarding the merger and the way Pfizer has gone about the management changes, we don’t expect a favourable ratio for Parke Davis.



    Equitymaster requests your view! Post a comment on "Parke Davis: Uncertainty affects valuation". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 02:22 PM